How many employees does Xeris Biopharma Holdings, Inc. have?

Xeris Biopharma Holdings, Inc. reported 435 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 2, 2026. That is up 10.4% from a year earlier.

What is Xeris Biopharma Holdings, Inc.'s revenue per employee?

Xeris Biopharma Holdings, Inc. brought in $292M of revenue in fiscal Dec 2025, which is $671K per employee. That ranks 45 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Xeris Biopharma Holdings, Inc. employees and revenue per employee

XERS · Biotechnology · $1.81B market cap

Xeris Biopharma Holdings, Inc. had 435 employees at the end of fiscal Dec 2025, up 10.4% from a year earlier. Revenue for the year was $292M, up 43.7% from a year earlier, or $671K per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

435

+10.4% YoY

Revenue

$292M

+43.7% YoY

Revenue / employee

$671K

Peer median $459K

Rank in industry

45 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2021

Hover a year for the numbers.

XERS employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	435	$292M	$671K	+10.4%	+43.7%
Dec 2024	394	$203M	$515K	+4.5%	+23.9%
Dec 2023	377	$164M	$435K	+6.2%	+48.7%
Dec 2022	355	$110M	$311K	+20.7%	+122.3%
Dec 2021	294	$49.6M	$169K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Xeris Biopharma Holdings, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
LGND Ligand Pharmaceuticals Incorporated	47	$268M	$5.70M	Leaner
RIGL Rigel Pharmaceuticals, Inc.	172	$294M	$1.71M	Efficient growth
CRMD CorMedix Inc.	191	$312M	$1.63M	Efficient growth
ARVN Arvinas, Inc.	246	$263M	$1.07M	Contracting
VCEL Vericel Corporation	398	$276M	$694K	Efficient growth
XERS Xeris Biopharma Holdings, Inc.	435	$292M	$671K	Efficient growth
ADPT Adaptive Biotechnologies Corporation	624	$277M	$444K	Efficient growth
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
IOVA Iovance Biotherapeutics, Inc.	975	$264M	$270K	Efficient growth

Every Healthcare company

Questions about Xeris Biopharma Holdings, Inc.

How many employees does Xeris Biopharma Holdings, Inc. have?: Xeris Biopharma Holdings, Inc. reported 435 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 2, 2026. That is up 10.4% from a year earlier.
What is Xeris Biopharma Holdings, Inc.'s revenue per employee?: Xeris Biopharma Holdings, Inc. brought in $292M of revenue in fiscal Dec 2025, which is $671K per employee. That ranks 45 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare XERS with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Xeris Biopharma Holdings, Inc.'s annual reports (Form 10-K), latest filed March 2, 2026. This is data, not a recommendation to buy or sell XERS.